People who are living with a rare and serious bleeding disorder will now have one-stop access to educational resources, financial support, and community connection programs through CSL Behring’s MySource™ program. Launched during the National Hemophilia Foundation’s (NHF) 65th Annual Meeting, MySource allows patients, caregivers and healthcare professionals to quickly and easily access CSL Behring’s patient-support resources at one online location www.MySourceCSL.com or with a one-on-one care coordinator (at 1-800-676-4266).
“CSL Behring has a broad portfolio of coagulation products, a long history of advancing coagulation therapy, and a thorough understanding of the challenges facing the bleeding disorders community,” said Lynne Powell, Senior Vice President, North America Commercial Operations, CSL Behring. “We are committed to providing treatments and supportive services, like MySource, that make a meaningful difference in the lives of people with bleeding disorders and those who care for them. We are proud to launch the program during NHF’s annual meeting.”
CSL Behring created MySource to provide members of the bleeding disorders community with a single source of information that will enhance their treatment experience. MySource is also designed to meet the specific needs and preferences of each patient by providing customized information each time they visit. MySource offers:
- Education opportunities that provide members of the bleeding disorders community with information about hemophilia and von Willebrand disease (VWD)
- Financial support programs to help ensure individuals are able to access their treatment
- Community connections that allow members of the bleeding disorders community to share experiences with one another, both online and in person
“For those living with a bleeding disorder, it can be difficult to find a central location for information about their condition. It can also be difficult to connect with a community for help in navigating the challenges associated with a bleeding disorder,” said Timothy Grams, who lives with severe hemophilia A. “The new MySource resource is a welcome addition to address this need. The site provides a wealth of information for patients and caregivers alike who are looking to learn more about the condition that affects them or to connect with others who share similar experiences and challenges.”
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.
###
Media Contact:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring
1-610-878-4841
greg.healy@cslbehring.com